Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor
Background Misoprostol is an effective agent for the induction of labor. Existing guidelines recommend oral misoprostol solution 25 μg every 2 hours. However, more research is required to optimize the use of oral misoprostol solution for the induction of labor. Objective The purpose of this study wa...
Gespeichert in:
Veröffentlicht in: | American journal of obstetrics and gynecology 2017-04, Vol.216 (4), p.405.e1-405.e6 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 405.e6 |
---|---|
container_issue | 4 |
container_start_page | 405.e1 |
container_title | American journal of obstetrics and gynecology |
container_volume | 216 |
creator | Rouzi, Abdulrahim A., MBChB Alsahly, Nora, MBChB Alamoudi, Rana, MBChB Almansouri, Nisma, MBChB Alsinani, Nawal, MBChB Alkafy, Souzan, MBChB Rozzah, Rayyan, MBCHB Abduljabbar, Hassan, MBChB |
description | Background Misoprostol is an effective agent for the induction of labor. Existing guidelines recommend oral misoprostol solution 25 μg every 2 hours. However, more research is required to optimize the use of oral misoprostol solution for the induction of labor. Objective The purpose of this study was to compare efficacy and safety of hourly titrated-dose oral misoprostol solution with static-dose oral misoprostol solution every 2 hours for labor induction. Study Design In this randomized controlled study, oral misoprostol solution was administered as (1) 20 μg hourly (≤4 doses) that was increased in the absence of regular uterine contractions to 40 μg hourly (≤4 doses) and then to 60 μg hourly (≤16 doses) or (2) 25 μg every 2 hours until active labor began (≤12 doses). A sample size of 146 women was planned with the use of a projected 95% rate for the primary endpoint (vaginal delivery within 24 hours) for hourly titrated-dose misoprostol and 80% rate for static-dose misoprostol every 2 hours. Safety outcomes included maternal morbidity and adverse neonatal outcomes. Results From December 2013 to July 2015, 146 women were assigned randomly to treatment. Demographic and clinical factors were similar between groups, except for age. Vaginal delivery was achieved within 24 hours in 47 women (64.4%) who received hourly titrated-doses of misoprostol solution and 48 women (65.8%) who received 2-hourly static-dose misoprostol solution ( P =1.00). Rates of vaginal delivery within 24 hours did not differ significantly between treatment groups for women who were nulliparous ( P =1.00) or who had postterm pregnancies ( P =.66), a Bishop score of ≤3 ( P =.84), or oxytocin augmentation ( P =.83). Cesarean deliveries were performed within 24 hours in 9 women who received hourly titrated-dose misoprostol solution and 2 women who received 2-hourly static-dose misoprostol solution ( P =.056). Pyrexia and meconium-stained liquor occurred more frequently with the hourly titrated-dose regimen. Conclusion The static-dose oral misoprostol solution every 2 hours has similar efficacy as hourly titrated-dose misoprostol solution but with fewer side-effects and lower complication rates. |
doi_str_mv | 10.1016/j.ajog.2016.11.1054 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852693096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S000293781632169X</els_id><sourcerecordid>1852693096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-2c64abc067d4b529eb4b5f04ce24755ce29d103119d00a3cf97107b3f00f80d63</originalsourceid><addsrcrecordid>eNqFUU1v1DAQtRAV3RZ-ARLykUuWsZM48QEkVAFFqoTUgsTNcuwJOHjjYjtF21-Pw3Y5cOHi8Yzem4_3CHnOYMuAiVfTVk_h25aX_5axUmubR2TDQHaV6EX_mGwAgFey7vpTcpbStKZc8ifklHeyF41gG3J3rWcbdu4eLTXezc5oT3N05R0w_0Kc6fewRL-n2eWoc4EVAuXHaso6O0NDLISdS-E2hpSDpyn4Jbsw0zFE6ma7mD9ZGKnXQ4hPycmofcJnD_GcfHn_7vPFZXX16cPHi7dXlWlamStuRKMHA6KzzdByiUMJIzQGedO1bQnSMqgZkxZA12aUHYNuqEeAsQcr6nPy8tC37PVzwZRVWdKg93rGsCTF-pYLWYNcofUBasoJKeKobqPb6bhXDNQquJrUKrhaBVeMqVXwwnrxMGAZdmj_co4KF8DrAwDLmXcOo0rG4WzQuogmKxvcfwa8-Yd_tOkH7jFNxYa5KKiYSlyBullNXi1nouZMyK_1b5MRqNo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1852693096</pqid></control><display><type>article</type><title>Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rouzi, Abdulrahim A., MBChB ; Alsahly, Nora, MBChB ; Alamoudi, Rana, MBChB ; Almansouri, Nisma, MBChB ; Alsinani, Nawal, MBChB ; Alkafy, Souzan, MBChB ; Rozzah, Rayyan, MBCHB ; Abduljabbar, Hassan, MBChB</creator><creatorcontrib>Rouzi, Abdulrahim A., MBChB ; Alsahly, Nora, MBChB ; Alamoudi, Rana, MBChB ; Almansouri, Nisma, MBChB ; Alsinani, Nawal, MBChB ; Alkafy, Souzan, MBChB ; Rozzah, Rayyan, MBCHB ; Abduljabbar, Hassan, MBChB</creatorcontrib><description>Background Misoprostol is an effective agent for the induction of labor. Existing guidelines recommend oral misoprostol solution 25 μg every 2 hours. However, more research is required to optimize the use of oral misoprostol solution for the induction of labor. Objective The purpose of this study was to compare efficacy and safety of hourly titrated-dose oral misoprostol solution with static-dose oral misoprostol solution every 2 hours for labor induction. Study Design In this randomized controlled study, oral misoprostol solution was administered as (1) 20 μg hourly (≤4 doses) that was increased in the absence of regular uterine contractions to 40 μg hourly (≤4 doses) and then to 60 μg hourly (≤16 doses) or (2) 25 μg every 2 hours until active labor began (≤12 doses). A sample size of 146 women was planned with the use of a projected 95% rate for the primary endpoint (vaginal delivery within 24 hours) for hourly titrated-dose misoprostol and 80% rate for static-dose misoprostol every 2 hours. Safety outcomes included maternal morbidity and adverse neonatal outcomes. Results From December 2013 to July 2015, 146 women were assigned randomly to treatment. Demographic and clinical factors were similar between groups, except for age. Vaginal delivery was achieved within 24 hours in 47 women (64.4%) who received hourly titrated-doses of misoprostol solution and 48 women (65.8%) who received 2-hourly static-dose misoprostol solution ( P =1.00). Rates of vaginal delivery within 24 hours did not differ significantly between treatment groups for women who were nulliparous ( P =1.00) or who had postterm pregnancies ( P =.66), a Bishop score of ≤3 ( P =.84), or oxytocin augmentation ( P =.83). Cesarean deliveries were performed within 24 hours in 9 women who received hourly titrated-dose misoprostol solution and 2 women who received 2-hourly static-dose misoprostol solution ( P =.056). Pyrexia and meconium-stained liquor occurred more frequently with the hourly titrated-dose regimen. Conclusion The static-dose oral misoprostol solution every 2 hours has similar efficacy as hourly titrated-dose misoprostol solution but with fewer side-effects and lower complication rates.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/j.ajog.2016.11.1054</identifier><identifier>PMID: 27986461</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Adolescent ; Adult ; Cervical Ripening - drug effects ; Delivery, Obstetric ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Fever - epidemiology ; Humans ; Labor, Induced ; Meconium ; misoprostol ; Misoprostol - administration & dosage ; Obstetrics and Gynecology ; oral ; Oxytocics - administration & dosage ; Pregnancy ; solution ; static ; Time Factors ; titrated ; Young Adult</subject><ispartof>American journal of obstetrics and gynecology, 2017-04, Vol.216 (4), p.405.e1-405.e6</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-2c64abc067d4b529eb4b5f04ce24755ce29d103119d00a3cf97107b3f00f80d63</citedby><cites>FETCH-LOGICAL-c459t-2c64abc067d4b529eb4b5f04ce24755ce29d103119d00a3cf97107b3f00f80d63</cites><orcidid>0000-0001-8601-0397</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajog.2016.11.1054$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27986461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rouzi, Abdulrahim A., MBChB</creatorcontrib><creatorcontrib>Alsahly, Nora, MBChB</creatorcontrib><creatorcontrib>Alamoudi, Rana, MBChB</creatorcontrib><creatorcontrib>Almansouri, Nisma, MBChB</creatorcontrib><creatorcontrib>Alsinani, Nawal, MBChB</creatorcontrib><creatorcontrib>Alkafy, Souzan, MBChB</creatorcontrib><creatorcontrib>Rozzah, Rayyan, MBCHB</creatorcontrib><creatorcontrib>Abduljabbar, Hassan, MBChB</creatorcontrib><title>Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>Background Misoprostol is an effective agent for the induction of labor. Existing guidelines recommend oral misoprostol solution 25 μg every 2 hours. However, more research is required to optimize the use of oral misoprostol solution for the induction of labor. Objective The purpose of this study was to compare efficacy and safety of hourly titrated-dose oral misoprostol solution with static-dose oral misoprostol solution every 2 hours for labor induction. Study Design In this randomized controlled study, oral misoprostol solution was administered as (1) 20 μg hourly (≤4 doses) that was increased in the absence of regular uterine contractions to 40 μg hourly (≤4 doses) and then to 60 μg hourly (≤16 doses) or (2) 25 μg every 2 hours until active labor began (≤12 doses). A sample size of 146 women was planned with the use of a projected 95% rate for the primary endpoint (vaginal delivery within 24 hours) for hourly titrated-dose misoprostol and 80% rate for static-dose misoprostol every 2 hours. Safety outcomes included maternal morbidity and adverse neonatal outcomes. Results From December 2013 to July 2015, 146 women were assigned randomly to treatment. Demographic and clinical factors were similar between groups, except for age. Vaginal delivery was achieved within 24 hours in 47 women (64.4%) who received hourly titrated-doses of misoprostol solution and 48 women (65.8%) who received 2-hourly static-dose misoprostol solution ( P =1.00). Rates of vaginal delivery within 24 hours did not differ significantly between treatment groups for women who were nulliparous ( P =1.00) or who had postterm pregnancies ( P =.66), a Bishop score of ≤3 ( P =.84), or oxytocin augmentation ( P =.83). Cesarean deliveries were performed within 24 hours in 9 women who received hourly titrated-dose misoprostol solution and 2 women who received 2-hourly static-dose misoprostol solution ( P =.056). Pyrexia and meconium-stained liquor occurred more frequently with the hourly titrated-dose regimen. Conclusion The static-dose oral misoprostol solution every 2 hours has similar efficacy as hourly titrated-dose misoprostol solution but with fewer side-effects and lower complication rates.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Cervical Ripening - drug effects</subject><subject>Delivery, Obstetric</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fever - epidemiology</subject><subject>Humans</subject><subject>Labor, Induced</subject><subject>Meconium</subject><subject>misoprostol</subject><subject>Misoprostol - administration & dosage</subject><subject>Obstetrics and Gynecology</subject><subject>oral</subject><subject>Oxytocics - administration & dosage</subject><subject>Pregnancy</subject><subject>solution</subject><subject>static</subject><subject>Time Factors</subject><subject>titrated</subject><subject>Young Adult</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAQtRAV3RZ-ARLykUuWsZM48QEkVAFFqoTUgsTNcuwJOHjjYjtF21-Pw3Y5cOHi8Yzem4_3CHnOYMuAiVfTVk_h25aX_5axUmubR2TDQHaV6EX_mGwAgFey7vpTcpbStKZc8ifklHeyF41gG3J3rWcbdu4eLTXezc5oT3N05R0w_0Kc6fewRL-n2eWoc4EVAuXHaso6O0NDLISdS-E2hpSDpyn4Jbsw0zFE6ma7mD9ZGKnXQ4hPycmofcJnD_GcfHn_7vPFZXX16cPHi7dXlWlamStuRKMHA6KzzdByiUMJIzQGedO1bQnSMqgZkxZA12aUHYNuqEeAsQcr6nPy8tC37PVzwZRVWdKg93rGsCTF-pYLWYNcofUBasoJKeKobqPb6bhXDNQquJrUKrhaBVeMqVXwwnrxMGAZdmj_co4KF8DrAwDLmXcOo0rG4WzQuogmKxvcfwa8-Yd_tOkH7jFNxYa5KKiYSlyBullNXi1nouZMyK_1b5MRqNo</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Rouzi, Abdulrahim A., MBChB</creator><creator>Alsahly, Nora, MBChB</creator><creator>Alamoudi, Rana, MBChB</creator><creator>Almansouri, Nisma, MBChB</creator><creator>Alsinani, Nawal, MBChB</creator><creator>Alkafy, Souzan, MBChB</creator><creator>Rozzah, Rayyan, MBCHB</creator><creator>Abduljabbar, Hassan, MBChB</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8601-0397</orcidid></search><sort><creationdate>20170401</creationdate><title>Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor</title><author>Rouzi, Abdulrahim A., MBChB ; Alsahly, Nora, MBChB ; Alamoudi, Rana, MBChB ; Almansouri, Nisma, MBChB ; Alsinani, Nawal, MBChB ; Alkafy, Souzan, MBChB ; Rozzah, Rayyan, MBCHB ; Abduljabbar, Hassan, MBChB</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-2c64abc067d4b529eb4b5f04ce24755ce29d103119d00a3cf97107b3f00f80d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Cervical Ripening - drug effects</topic><topic>Delivery, Obstetric</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fever - epidemiology</topic><topic>Humans</topic><topic>Labor, Induced</topic><topic>Meconium</topic><topic>misoprostol</topic><topic>Misoprostol - administration & dosage</topic><topic>Obstetrics and Gynecology</topic><topic>oral</topic><topic>Oxytocics - administration & dosage</topic><topic>Pregnancy</topic><topic>solution</topic><topic>static</topic><topic>Time Factors</topic><topic>titrated</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rouzi, Abdulrahim A., MBChB</creatorcontrib><creatorcontrib>Alsahly, Nora, MBChB</creatorcontrib><creatorcontrib>Alamoudi, Rana, MBChB</creatorcontrib><creatorcontrib>Almansouri, Nisma, MBChB</creatorcontrib><creatorcontrib>Alsinani, Nawal, MBChB</creatorcontrib><creatorcontrib>Alkafy, Souzan, MBChB</creatorcontrib><creatorcontrib>Rozzah, Rayyan, MBCHB</creatorcontrib><creatorcontrib>Abduljabbar, Hassan, MBChB</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rouzi, Abdulrahim A., MBChB</au><au>Alsahly, Nora, MBChB</au><au>Alamoudi, Rana, MBChB</au><au>Almansouri, Nisma, MBChB</au><au>Alsinani, Nawal, MBChB</au><au>Alkafy, Souzan, MBChB</au><au>Rozzah, Rayyan, MBCHB</au><au>Abduljabbar, Hassan, MBChB</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>216</volume><issue>4</issue><spage>405.e1</spage><epage>405.e6</epage><pages>405.e1-405.e6</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><abstract>Background Misoprostol is an effective agent for the induction of labor. Existing guidelines recommend oral misoprostol solution 25 μg every 2 hours. However, more research is required to optimize the use of oral misoprostol solution for the induction of labor. Objective The purpose of this study was to compare efficacy and safety of hourly titrated-dose oral misoprostol solution with static-dose oral misoprostol solution every 2 hours for labor induction. Study Design In this randomized controlled study, oral misoprostol solution was administered as (1) 20 μg hourly (≤4 doses) that was increased in the absence of regular uterine contractions to 40 μg hourly (≤4 doses) and then to 60 μg hourly (≤16 doses) or (2) 25 μg every 2 hours until active labor began (≤12 doses). A sample size of 146 women was planned with the use of a projected 95% rate for the primary endpoint (vaginal delivery within 24 hours) for hourly titrated-dose misoprostol and 80% rate for static-dose misoprostol every 2 hours. Safety outcomes included maternal morbidity and adverse neonatal outcomes. Results From December 2013 to July 2015, 146 women were assigned randomly to treatment. Demographic and clinical factors were similar between groups, except for age. Vaginal delivery was achieved within 24 hours in 47 women (64.4%) who received hourly titrated-doses of misoprostol solution and 48 women (65.8%) who received 2-hourly static-dose misoprostol solution ( P =1.00). Rates of vaginal delivery within 24 hours did not differ significantly between treatment groups for women who were nulliparous ( P =1.00) or who had postterm pregnancies ( P =.66), a Bishop score of ≤3 ( P =.84), or oxytocin augmentation ( P =.83). Cesarean deliveries were performed within 24 hours in 9 women who received hourly titrated-dose misoprostol solution and 2 women who received 2-hourly static-dose misoprostol solution ( P =.056). Pyrexia and meconium-stained liquor occurred more frequently with the hourly titrated-dose regimen. Conclusion The static-dose oral misoprostol solution every 2 hours has similar efficacy as hourly titrated-dose misoprostol solution but with fewer side-effects and lower complication rates.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27986461</pmid><doi>10.1016/j.ajog.2016.11.1054</doi><orcidid>https://orcid.org/0000-0001-8601-0397</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9378 |
ispartof | American journal of obstetrics and gynecology, 2017-04, Vol.216 (4), p.405.e1-405.e6 |
issn | 0002-9378 1097-6868 |
language | eng |
recordid | cdi_proquest_miscellaneous_1852693096 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Administration, Oral Adolescent Adult Cervical Ripening - drug effects Delivery, Obstetric Dose-Response Relationship, Drug Drug Administration Schedule Female Fever - epidemiology Humans Labor, Induced Meconium misoprostol Misoprostol - administration & dosage Obstetrics and Gynecology oral Oxytocics - administration & dosage Pregnancy solution static Time Factors titrated Young Adult |
title | Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A39%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20clinical%20trial%20between%20hourly%20titrated%20and%202%20hourly%20static%20oral%20misoprostol%20solution%20for%20induction%20of%20labor&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Rouzi,%20Abdulrahim%20A.,%20MBChB&rft.date=2017-04-01&rft.volume=216&rft.issue=4&rft.spage=405.e1&rft.epage=405.e6&rft.pages=405.e1-405.e6&rft.issn=0002-9378&rft.eissn=1097-6868&rft_id=info:doi/10.1016/j.ajog.2016.11.1054&rft_dat=%3Cproquest_cross%3E1852693096%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1852693096&rft_id=info:pmid/27986461&rft_els_id=1_s2_0_S000293781632169X&rfr_iscdi=true |